Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

71 results about "Prognosis Marker" patented technology

Keywords: prognosis, prognostic tumour marker, biomarker, primary studies, evidence synthesis, guidelines In oncology, prognostic markers (also called prognostic factors) are clinical measures used to help elicit an individual patient's risk of a future outcome, such as recurrence of disease after primary treatment.

Application of reagent for detecting expression quantity of biomarker in preparation of product for evaluating prognosis of kidney cancer and kit for evaluating prognosis of kidney cancer

The invention discloses an application of a reagent for detecting the expression quantity of a biomarker in preparation of a product for evaluating the prognosis of kidney cancer and a kit for evaluating the prognosis of kidney cancer, the expression quantity comprises the expression quantity of mRNA level and protein level, and the biomarker comprises a first biomarker and / or a second biomarker, the first biomarker comprises the following genes: FOS, JUNB, EGR1, NR4A1, IER2 and ATF3, and the second biomarker comprises at least one of the following genes: SLC16A9, SLC13A1, CYP4A11 and ESRRG. According to the application, multiple omics analysis means are integrated, the prognosis marker, namely the biomarker, of the kidney cancer is screened and identified, and the prognosis of a kidney cancer patient can be judged by detecting the biomarker, so that accurate treatment and whole-course disease management are facilitated, and the survival of the patient is improved.
Owner:PEKING UNIVERSITY SHENZHEN HOSPITAL

Application of tsRNA-3025a as acute myocardial infarction prognostic marker and myocardial ischemia-reperfusion injury treatment target

PendingCN121975930AEffectively assess heart failureEffectively assess riskOrganic active ingredientsMicrobiological testing/measurementPharmaceutical drugAntagomir
The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.
Owner:SHANGHAI TONGREN HOSPITAL

Application of HOXD1 in diagnosis, prognosis and treatment of liver cancer

The invention discloses application of HOXD1 in diagnosis, prognosis and treatment of liver cancer, and particularly relates to application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for diagnosing a liver cancer object. The invention discloses application of a reagent for detecting expression of a biomarker HOXD1 in preparation of a product for prognosis of a liver cancer object. The invention discloses an application of HOXD1 as a target in screening medicines for treating liver cancer. The HOXD1 expression inhibitor is applied to preparation of a medicine for treating liver cancer. Differential expression of the HOXD1 in hepatocellular carcinoma tissues and normal hepatocellular carcinoma tissues is clear through research, high expression of the HOXD1 is closely related to the survival reduction period of clinical hepatocellular carcinoma patients, specific knock-down of the HOXD1 can obviously reduce the proliferation capacity of the hepatocellular carcinoma, and a new diagnosis / prognosis marker and a treatment target are provided for early discovery, early treatment and prognosis of the hepatocellular carcinoma. And a new treatment strategy and direction are provided.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of SHC3 as diagnosis and prognosis marker and treatment target of lung metastasis of breast cancer

The invention discloses application of SHC3 as a diagnosis and prognosis marker and a treatment target of lung metastasis of breast cancer. The research shows that the expression of SHC3 in TNBC lung metastatic cells is remarkably up-regulated, and the up-regulation is closely related to the prognosis of TNBC patients; the increase of SHC3 expression is positively correlated with the migration ability of the TNBC cells, which proves that the SHC3 gene is obviously up-regulated in the TNBC cells of pneumophilic metastasis and can be used as a biomarker of lung metastasis of breast cancer; researches show that silence of SHC3 can significantly weaken the metastasis ability of TNBC and reduce the number of pulmonary metastasis nodules, overexpression of SHC3 can enhance the metastasis activity of TNBC, and SHC3 can be used as a therapeutic target of breast cancer pulmonary metastasis; the invention provides a new marker for prognosis of breast cancer and diagnosis of lung metastasis of breast cancer, and provides a new target and treatment strategy and direction for treatment of lung metastasis of breast cancer.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of bacteria as nasopharynx cancer detection, treatment or prognosis marker

The invention belongs to the field of biological medicine, and relates to application of bacteria as a marker for detection, treatment or prognosis of nasopharyngeal carcinoma. As a marker, the bacterium disclosed by the invention can be used for prevention, diagnosis, treatment and prognosis intervention of nasopharynx cancer. Through verification, the marker has relatively high diagnosis efficiency and accuracy on diagnosis and prognosis of nasopharynx cancer, an economical, simple and convenient solution is provided for clinic, and a new insight is also provided for accurate individualized treatment of nasopharynx cancer patients.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Combination of SLC8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma

PCT designated stage expiredWO2024245951A1Compound screeningApoptosis detectionEfficacyOncology
Metastatic uveal melanomas are highly resistant to all existing treatments. Here, a kinome-wide CRISPR-Cas9 knockout screen, revealed that the LKB1-SIK2 module plays a critical role in constraining uveal melanoma cell tumorigenesis. The inventors' results demonstrate that a combination of SLC8A1 inhibitor and mitochondria-targeted antioxidant has an enhanced cell death efficacy in LKB1 and SIK2-negative uveal melanoma cells. They also designed a LKB1 loss gene signature that is predictive of patient survival and treatment response. Their data thus identify new prognosis markers, and metabolic vulnerability, thereby providing a therapeutic strategy for these subtypes of metastatic uveal melanomas. The present invention relates to a method for treating melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a combination of SLC8A1 inhibitor and mitochondria-targeted antioxidant.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1

Use of LMP1 gene copy number variation detection reagent in preparation of NK / t cell lymphoma prognosis kit

Disclosed in the present invention is a use of an MP1 gene copy number variation detection reagent in preparation of an NK / T cell lymphoma prognosis kit. The present invention further provides a detection kit comprising the LMP1 gene copy number variation detection reagent, a use thereof, and an NK / T cell lymphoma prognosis method. In the present invention, a copy number variation event of LMP1 gene in an EB virus genome is used as a novel prognosis marker, which has a good prediction value for the overall survival and progression-free survival prognosis of an NK / T cell lymphoma patient, and can realize more accurate and effective prognostic assessment for the NK / T cell lymphoma patient.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Colorectal cancer liver metastasis prognosis marker and dynamic prognosis prediction method

The invention discloses a prognosis marker and a dynamic prognosis prediction method for colorectal cancer liver metastasis. The method comprises the following steps: S1, acquiring clinical pathological characteristic data of a patient with colorectal cancer liver metastasis and a longitudinal laboratory marker measured during post-operation follow-up visit; s2, extracting a change trend of the longitudinal laboratory marker by utilizing multivariable function principal component analysis to obtain a principal component score; s3, training a random survival forest model by using the principal component score and the clinical pathological feature data to obtain a dynamic prediction model; s4, dynamically updating the score of the principal component based on a newly collected laboratory marker of postoperative follow-up visit of the patient, and outputting dynamic risk assessment results of the progression-free lifetime and the total lifetime of the patient through a dynamic prediction model; according to the method, the prediction model capable of dynamically evaluating the survival risk of the patient is constructed and updated by fusing the dynamic longitudinal laboratory marker and the static clinical pathological characteristics.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Application of ADAMTS2 related to gastric cancer

The invention relates to application of ADAMTS2 related to gastric cancer. The application comprises an application of the ADAMTS2 inhibitor in preparation of drugs for preventing, relieving and / or treating gastric cancer, an application of a reagent for detecting ADAMTS2 and / or COL3A1 in preparation of a kit or system for predicting gastric cancer prognosis, and a system or a prognosis instrument for predicting gastric cancer prognosis. The metalloproteinase ADAMTS2 is found to be remarkably and highly expressed in gastric cancer tissues and is associated with peritoneal metastasis and tumor dryness. Therefore, ADAMTS2 can be used as a diagnosis and prognosis marker and a treatment target of cervical cancer, and has a huge application prospect.
Owner:WUHAN BLOOD CENTER +1

Pregnostic marker gene related to sepsis blood coagulation and application of prognostic marker gene in preparation of sepsis prognosis prediction and diagnosis product

The invention discloses a sepsis blood coagulation related prognosis marker gene and application thereof in preparation of sepsis prognosis prediction and diagnosis products, and belongs to the technical field of biology. The sepsis blood coagulation related prognostic marker genes are composed of WFDC1, FGFBP2, CX3CR1, GIMAP4, ELANE and DEFA4, and a prognostic scoring system (a sepsis prognostic risk prediction model) is further established based on the six sepsis blood coagulation related prognostic marker genes. A time-dependent ROC curve and multivariable Cox regression analysis show that the discrimination capability of six gene prognosis scoring systems developed by the invention on the total survival rate (OS) is superior to that of other clinical factors (age and gender), and the area under a three-week curve is not inferior to the area within one or two weeks; therefore, the prediction scoring system has lasting and relatively independent discrimination capability on the prognosis of the sepsis patient.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV

Prognostic molecular markers specific for squamous and adenocarcinoma of the cervix and uses thereof

The application provides a molecular marker for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma and application thereof, and belongs to the technical field of biological detection. Through bioinformatics analysis methods such as multivariate statistical analysis, difference screening, single factor COX regression analysis and multi-factor COX regression analysis, the application obtains an adenine kinase 4 used for evaluating the prognosis marker of cervical squamous cell carcinoma and a brain sponge-shaped deformity 2 protein used for evaluating the prognosis biomarker of cervical adenocarcinoma. Based on the biomarkers of the application, a kit for evaluating cervical squamous cell carcinoma or adenocarcinoma is constructed, which is used for accurately evaluating the prognosis of cervical squamous cell carcinoma or adenocarcinoma.
Owner:ZHEJIANG CANCER HOSPITAL +1

Application of MISP as breast cancer diagnosis / prognosis marker and treatment target

The invention discloses application of MISP as a breast cancer diagnosis / prognosis marker and a treatment target. The in-depth study on the expression of MISP in breast cancer cells and the influence on malignant biological behaviors such as breast cancer proliferation shows that compared with normal breast epithelial cells, the MISP is highly expressed in the breast cancer cells, the expression of the MISP is highly related to poor clinical prognosis of breast cancer patients, and the proliferation of the breast cancer cells can be inhibited by reducing the expression of the MISP. A new biomarker is provided for diagnosis and prognosis of the breast cancer, a new target spot is provided for treatment of the breast cancer, and important scientific significance is achieved in the aspects of subsequent drug research and development, clinical treatment and the like.
Owner:CHONGQING MEDICAL UNIVERSITY

A liver cancer prognosis marker and application thereof

The application discloses a liver cancer prognosis marker and application thereof, and the liver cancer prognosis marker comprises TXNRD1, HAO1, C1S, OPTN and SNX6. The application provides a group of liver cancer prognosis markers, and a liver cancer patient prognosis prediction model is constructed based on the liver cancer prognosis markers. The liver cancer prognosis markers are obtained through comprehensive gene expression levels, single cell analysis and spatial transcriptome analysis, and the diversity of the data set and the large sample quantity improve the reliability and universality of the liver cancer prognosis markers and the liver cancer patient prognosis prediction model.
Owner:SHENZHEN PEOPLES HOSPITAL

Colorectum prognostic marker screening method and system

The invention provides a colorectum prognosis marker screening method and system, and relates to the technical field of data processing. The method comprises the following steps: collecting colorectum potential prognosis markers to form a colorectum potential prognosis set; collecting and screening crowd data, and performing classification division based on crowd sources to form different classified and screened crowd data; screening and analyzing all colorectal potential prognostic markers in the colorectal potential prognostic set according to diagnosis results for different classified screening population data to form prognostic marker screening data. According to the method, current possible markers are collected and reasonable analysis is carried out by using a proper diagnosis crowd, so that screening of a prognosis marker combination formed by a plurality of markers is realized, and a basis capable of reasonably carrying out colorectal prognosis analysis and judgment is formed.
Owner:THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV

New populations of fibroblasts and macrophages as prognosis markers for detection of fibroblasts associated diseases

PCT designated stage expiredWO2025027126A1Disease diagnosisFibroblastDisease progression
A method is disclosed for detecting if a subject is at risk of a fibroblast associated disease progression or for determining the clinical outcome of subjects suffering of such a disease, wherein the method comprises detecting SFRP1 positive, SFRP4 negative, FAP negative and RAMP1 negative fibroblasts (CXCL-iFibro) and, optionally, CD68 positive, CD206 positive and FOLR2 positive macrophages in a biological sample from said subject. The presence of CXCL-iFibro is indicative of disease progression and of a poor prognosis.
Owner:INSTITUT CURIE +1

Gastric adenocarcinoma prognosis marker and clinical prognosis prediction model

The invention discloses a prognostic marker for gastric adenocarcinoma. The prognostic marker is composed of eight genes, namely F5, SLC5A1, PHYHD1, FNDC1, NFE2L3, SCUBE2, CBS and CTHRC1. A risk assessment model constructed on the basis of the eight genes is beneficial for better predicting the prognosis condition of a gastric adenocarcinoma patient, effectively evaluating the prognosis risk of different patients and performing early intervention, and brings great help for guiding clinical treatment of the disease, so that the five-year survival rate of the gastric adenocarcinoma patient is increased. The risk assessment model is high in prediction accuracy, has universality, is remarkably superior to other gastric adenocarcinoma prognosis methods in the prior art, and is also remarkably superior to other models constructed in the research process.
Owner:HANGZHOU INSTITUTE OF MEDICAL SCIENCES CHINESE ACADEMY OF SCIENCES

Use of reagent for detecting C1QBP protein expression level in preparation for oral cancer screening or prognosis kit

A C1QBP protein can be used in preparation for an oral cancer screening or prognosis marker. A reagent for detecting a C1QBP protein expression level is in preparation for an oral cancer screening or prognosis kit. The C1QBP protein expression level in an oral mucosa tissue of a patient suffering from oral squamous cell carcinoma is found to be remarkably higher than that of a healthy patient. Using a reagent for detecting a C1QBP protein expression level for preparing a screening or prognosis kit of oral squamous cell carcinoma can realize effective screening or prognosis of oral squamous cell carcinoma.
Owner:SICHUAN UNIV

Biliary atresia differential diagnosis and prognosis marker and application thereof

PendingCN121951023AGood combination performancehigh diagnostic valueMicrobiological testing/measurementMedical automated diagnosisLiver functionsDisease
The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.
Owner:WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY

Pancreatic cancer diagnosis marker based on external vesicle miRNA and application thereof

The invention is a divisional application of which the application number is 202411480045.3. The invention provides a pancreatic cancer diagnosis marker based on external vesicle miRNA (micro Ribonucleic Acid) and application of the pancreatic cancer diagnosis marker. The pancreatic cancer diagnosis or prognosis marker based on the extracellular vesicle miRNA relates to a miRNA combination with biological significance in serum or plasma extracellular vesicles, and does not take a conventional reference gene as a reference; the pancreatic cancer diagnosis model constructed by taking the expression quantity ratio of the paired miRNAs in the combination as the input characteristic of the model has high diagnosis sensitivity and specificity on pancreatic cancer, is suitable for different data centers, has good diagnosis stability, has great potential in early pancreatic cancer screening, and has good application prospects. The kit has important practical significance for early diagnosis or prognosis prediction of pancreatic cancer.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL +1

Use of tgm2 as a diagnostic, prognostic biomarker and therapeutic target for cervical cancer

The application discloses application of TGM2 as a cervical cancer diagnosis, prognosis biomarker and therapeutic target. The application provides a new cervical cancer diagnosis and prognosis marker TGM2, which can clearly characterize the occurrence and development of cervical cancer; the marker presents specific high expression phenomenon in comparison with normal tissue in human clinical cervical cancer tissue; and the marker also presents high expression in human cervical cancer cell lines. Knocking down TGM2 can inhibit the proliferation and migration ability of cervical cancer cells; TGM2, as an enzyme, has high application potential as a diagnosis and treatment target. The application provides a new marker and target for the diagnosis, prognosis and treatment of cervical cancer, and can provide a new strategy and direction for the treatment of cervical cancer.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of TOP1 as diagnostic and prognostic marker and therapeutic target of glioblastoma

The invention discloses application of a reagent for detecting expression of a biomarker TOP1 in preparation of a product for diagnosis or prognosis of a glioblastoma object and application of a TOP1 expression inhibitor in preparation of a medicine for treating glioblastoma. The research proves that the TOP1 can be used as a novel diagnosis and prognosis marker and a treatment target of glioblastoma, and a novel reference is provided for a precise tumor treatment scheme. A certain reference value is provided for subsequent further research on the specific action mechanism of TOP1 for promoting the glioblastoma cell function, and a new thought is provided for research on the pathogenesis of glioblastoma.
Owner:CHONGQING MEDICAL UNIVERSITY

Acute myelogenous leukemia prognostic marker and application thereof

The invention specifically discloses an acute myelogenous leukemia prognostic marker and application thereof, and relates to the technical field of biological medicines. The invention provides an application of a protein lysine succinylation modification level as an acute myelogenous leukemia diagnosis and / or prognosis marker, and clinical data, cell experiments and animal experiments prove that the protein lysine succinylation modification level is related to AML prognosis and is a supplement of an existing prognosis system. Ksuc can be detected through a multi-parameter flow type technology, the method is simple, convenient and rapid, the experimental period is only several hours, Ksuc can be obtained when conventional immune typing detection is carried out at the beginning of diseases, and the experimental period is shorter than that of existing prognosis factors adopting next-generation sequencing, traditional PCR and the like. The invention provides a theoretical basis and an experimental basis for developing a new treatment strategy, and has good clinical transformation and clinical application prospects.
Owner:ANHUI PROVINCIAL HOSPITAL

Lung adenocarcinoma prognosis marker and model

The application provides a lung adenocarcinoma prognosis marker and model, a lung adenocarcinoma prognosis model based on programmed cell death (PCD) related mRNA and lncRNA is constructed, and the biological function of the lncRNA model in lung adenocarcinoma is explored through bioinformatics analysis and experiments. The prognosis model covers all PCD pathways and various molecules, has a robust prognosis prediction accuracy, and can provide potential molecular targets for personalized treatment. The method of the application comprehensively constructs a lung adenocarcinoma diagnosis model suitable for Chinese population by using PCD related mRNA and lncRNA, enhances the recognition ability of tumor patient classification from multiple aspects, improves the accuracy and reliability of prognosis prediction, can provide strong support for promoting the personalized treatment strategy of lung adenocarcinoma patients, and is suitable for popularization and application.
Owner:ZHEJIANG UNIV

Application of RGS14 in preparation of kit for auxiliary diagnosis or prognosis of liver cancer and application of RGS14 expression inhibitor in preparation of medicine for treating liver cancer

The invention discloses application of RGS14 in preparation of a kit for auxiliary diagnosis or prognosis of liver cancer and application of an RGS14 expression inhibitor in preparation of a medicine for treating liver cancer. It is found for the first time that RGS14 expression in liver cancer is remarkably improved compared with para-carcinoma tissue, and high RGS14 expression is not beneficial to overall survival of liver cancer patients; and when the RGS14 is knocked down, the clone formation and migration of the liver cancer cells are obviously inhibited. The high expression of the RGS14 is closely related to the poor prognosis of the liver cancer patient, which prompts that the RGS14 can be used as a prognosis marker of the liver cancer, and effective information is provided for prognosis evaluation and curative effect monitoring of the liver cancer. The invention also provides an RGS14 expression inhibitor siRNA which has a good interference effect when being used for inhibiting the expression of RGS14 and has clinical application potential.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Use of HMGCL as a glioma diagnosis / prognosis marker and a therapeutic target

The present invention belongs to the technical fields of disease diagnosis and treatment and molecular biology, and particularly relates to the application of HMGCL as a glioma diagnosis / prognosis marker and a therapeutic target. The present invention demonstrates for the first time that the expression of HMGCL increases with the increase in the malignancy degree of glioma and is negatively correlated with the survival rate. At the same time, the HMGCL lentivirus can significantly reduce the expression level of HMGCL in glioma, and the knockdown of HMGCL inhibits the proliferation and colony formation of glioma cells, and can be used as an effective target for the prevention and / or treatment of glioma. In addition, the present invention demonstrates that the specific knockdown of HMGCL can lead to a significant decrease in the level of histone acetylation modification in GBM cells. In summary, the HMGCL and its molecular mechanism provided by the present invention will contribute to the in-depth understanding of the pathogenesis of glioma, and will also contribute to providing potential biomarkers and therapeutic targets for the clinical diagnosis, prognosis evaluation, prevention and treatment of glioma, and therefore has good practical application value.
Owner:SHANDONG UNIV

Hepatocellular carcinoma prognosis marker and application thereof

The invention particularly discloses a hepatocellular carcinoma prognostic marker and application thereof, and relates to the technical field of biological medicine. The invention provides the application of the expression level of the debranching enzyme homolog 1 as the hepatocellular carcinoma diagnosis and / or prognosis marker, compared with the traditional marker, the debranching enzyme homolog 1 more emphasizes screening or early diagnosis, and the DBR1 has potential value in reflecting tumor invasiveness and predicting patient prognosis. Experimental results show that high DBR1 expression is often related to poor prognosis indexes such as poor lifetime and high recurrence risk of liver cancer patients, and patients with low expression show relatively better prognosis. Due to the difference, the DBR1 can provide more accurate risk stratification basis for clinicians and help to formulate personalized treatment schemes and follow-up visit plans, theoretical basis and experimental basis are provided for developing new treatment strategies, and good clinical transformation and clinical application prospects are achieved.
Owner:UNIV OF SCI & TECH OF CHINA +1

Application of EDEM1 as anti-tumor drug adriamycin resistance marker and breast cancer prognosis marker

The invention relates to the technical field of biomedicine, in particular to application of EDEM1 as a doxorubicin drug resistance marker and a breast cancer prognosis marker. According to the application disclosed by the invention, the triple-negative breast cancer cells are firstly stimulated by an endoplasmic reticulum stress inducer, the EDEM1 content in the stimulated triple-negative breast cancer cells is found to be obviously increased, and a result shows that the EDEM1 plays an important role in an endoplasmic reticulum stress process. EDEM1 is subjected to overexpression or interference expression in triple-negative breast cancer cells, the result shows that EDEM1 can relieve endoplasmic reticulum stress caused by an endoplasmic reticulum stress inducer and adriamycin to the cells, the endoplasmic reticulum stress resistance of the triple-negative breast cancer cells is improved, and meanwhile, IC50 of breast cancer drug-resistant cells with interference expression of EDEM1 is lower than that of a control group; further, the EDEM1 can be proved to be used as a breast cancer adriamycin-resistant molecular target. Meanwhile, the EDEM1 content can be used as an independent prediction factor of the prognosis condition of the triple-negative breast cancer patient, and the EDEM1 content and the independent prediction factor are positively correlated.
Owner:SHANDONG UNIV QILU HOSPITAL

Construction method and verification method of melanoma prognosis model based on lactate gene methylation characteristics

The application relates to the technical field of melanoma prognosis, and provides a construction method and a verification method of a melanoma prognosis model based on a lactation gene methylation feature. The DNA methylation data of a cancer genome atlas database is taken as a training set, and the DNA methylation data of a gene expression comprehensive database is taken as a verification set, so that the lactation-related gene methylation feature prognosis marker model of melanoma constructed has good external applicability. A methylation site pair matrix is constructed through the relative methylation order relationship of the methylation sites, so that the batch effect between different data sets is effectively avoided, and excellent robustness and clinical applicability are achieved. The methylation sites corresponding to the lactation-related gene set are taken as anchor points to perform hierarchical clustering and differential methylation site screening, functional sites related to prognosis are screened out, the reliability of the constructed prognosis marker model is improved, and the accuracy of prognosis prediction is improved.
Owner:GANNAN MEDICAL UNIV

Bladder cancer prognosis marker and application thereof

The invention discloses a bladder cancer prognostic marker which comprises the following genes: PATZ1, TTC6, AEBP1 and MAOA, and further discloses application of a reagent for detecting the prognostic marker in preparation of bladder cancer related detection products, the bladder cancer prognostic marker provided by the invention is based on an FAM related gene set, molecular subtype clustering is carried out on BLCA to obtain two subtypes, and the two subtypes are used for detecting the bladder cancer. Two subtypes of DEGs are subjected to single-factor Cox regression analysis, four gene tags PATZ1, TTC6, AEBP1 and MAOA are established for a BLCA prognosis prediction model, and the prognosis condition of a patient is evaluated, so that the survival rate of the bladder cancer patient is favorably improved, a new thought is provided for clinical precise treatment decision of bladder cancer, and the selection of a clinical treatment scheme is facilitated.
Owner:THE THIRD PEOPLES HOSPITAL OF CHENGDU